Addendum
Pembrolizumab (cervical cancer, combination with chemoradiotherapy) – Addendum to Project A24-110
Report documents
-
Addendum
Pembrolizumab (cervical cancer, combination with chemoradiotherapy) – Addendum to Project A24-110
Dossier assessment
Indication:
Adults with International Federation of Gynecology and Obstetrics 2014 Stage III to IVA locally advanced cervical cancer who have not received prior definitive therapy
Result of dossier assessment:
Unchanged after addendum:
hint of non-quantifiable added benefit
Additional information
Federal Joint Committee (G-BA)
2025-05-D15 A G-BA decision was published.
Project details
- Project no.
- A25-43
- Commission
- Commission awarded on 25.03.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A25-43_en
Connected Projects
-
Dossier assessment
Pembrolizumab (cervical cancer, combination with chemoradiotherapy) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed